Reduced EHD2 expression was reported in esophageal, colorectal, breast, and hepatocellular cancers (Li et al., 2013; Guan et al., 2021; Yang et al., 2015; Liu et al., 2016), with in vitro knockdown or overexpression studies supporting a tumor suppressive role for EHD2. Here, EHD2 is linked to hepatocellular carcinoma.